Yanjie (Belle) BaoScientist II, Formulation Development
James BarlowDirector of the Board
James Barlow is a member of the Board of Directors of North American Health Care, Inc., a privately held company that provides contractual services to facilities specializing in post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations (5 continents, 23 countries), financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. (NYSE:AGN), he oversaw financial due diligence, integration and structuring for more than 100 asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed and more than $4.5billion in other transactions. He ensured consistent application of all corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities.
Hari BhaskaranScientist I, Transnational Biology
Jonathan BushResearch Associate I, Formulation Development
Arisa Iga CaleResearch Associate I, RNA Production
Lena CeballosSenior Research Associate, Analytical Development
Cheryl ChanIntern, Analytical Development
Hanyi (Han) ChangResearch Associate I, Formulation Development
Pad ChivukulaCSO, COO
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
ThanhChau DamResearch Associate II, Translational Biology
Jared DavisDirector, RNA Process Development
Peter FarrellChairman of the Board
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.
Nancy FuselliDirector, Quality & Regulatory Affairs
Christopher GaviganIntern, Frontier Science
Jose GonzalesResearch Associate II, Translational Biology
Carol HidalgoHuman Resources Consultant
Michael HodgesR&D & Medical Consultant
Xuequn (Helen) HuaDirector, Drug Discovery
Daniel HwangSenior Accountant
Manny JuarezFacilities, Shipping/Receiving Coordinator
Priya KarmaliSenior Director, Pharmaceutical Development
Priya Karmali is Senior Director of Pharmaceutical Development at Arcturus Therapeutics Ltd. Dr. Karmali joined Arcturus in 2015 and is responsible for research and development efforts for LUNAR™ technology, Arcturus’ lipid mediated nucleic acid delivery system. She has over 15 years of experience in the field of lipid-based drug delivery systems from discovery to development. Prior to Arcturus, Priya was Associate Director of Formulation Development at Regulus Therapeutics where she led drug product development efforts for miRNA therapeutic drugs currently in various stages of clinical trials. Prior to joining Regulus, Priya was a Principal Scientist at Nitto Denko where she led formulation development efforts for their Vitamin A targeted siRNA lipid nanoparticle for treatment of liver fibrosis. Dr. Karmali has a Ph.D. in Chemistry from the Indian Institute of Chemical Technology where she specialized in development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She is an author or inventor on over 35 scientific publications and patents.
Jae Heon (Jay) KimIntern, Formulation Development
Inna KoukharevaSenior Manager, Analytical Development
KC KummerfeldSenior Director, Finance & Corporate Controller
Yi KuoResearch Associate I, RNA Production
Thu LeIntern, Formulation Development
Allison LeeIntern, Formulation Development
Robin LeeSenior Research Associate, Formulation Development
Samuel LeeResearch Associate I, RNA Process Development
Sharon LeeResearch Associate I, Frontier Science
Angel LeuSenior Research Associate, Frontier Science
Pattraranee (Patty) LimphongSenior Manager, RNA Process Development
Steven LyResearch Associate I, Analytical Development
Maher AlayyoubiScientist II, RNA Process Development
Dr. Magda MarquetDirector of the Board
Dr. Magda Marquet is the co-founder and co-CEO of Alma Life Sciences, an investment and consulting firm with a portfolio of over twenty companies in the areas of diagnostics, digital health and pharmaceuticals, Chairman and co-Founder of Althea, an Ajinomoto company, and Co-founder of AltheaDx, a precision medicine company. She has three decades of experience in the biotechnology industry in the US and Europe. Prior to starting Althea, Dr. Marquet held management positions at Vical Inc., Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. She currently serves as a Board member for Sente, Independa and Portable Genomics. She is also co-Chairman of the Advisory Board of MD Revolution. Dr. Marquet was Chairman of BIOCOM (2013-2014) and is Chair of the Board of Visitors of the UCSD Moores Cancer Center. She serves as a Director of the Economic Development Corporation (EDC- Executive Committee) and of the Kyoto Symposium Organization. She is also a member of the UCSD Biological Sciences Dean Leadership Council and an advisor for the Chopra Foundation. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year Award in the Life Sciences category, the Athena Pinnacle Award and the Exemplary Service Award from the San Diego Business Journal. She is the first woman inducted in the Connect Entrepreneur Hall of Fame (2016) and the Director of the Year Award recipient (2016-Corporate Governance) from the Corporate Directors Forum.
Daiki MatsudaSenior Scientist, Frontier Science
Mike MatsumotoResearch Associate I, Drug Discovery
Kim McAdenPurchasing Manager
Rajesh MukthavaramScientist I, Formulation Development
Michelle NguyenResearch Associate I, Analytical Development
Jocelyn OngFront Desk Coordinator/Administrative Assistant I
Parsa ParirokhResearch Associate I, RNA Process Development
Jenny ParkScientist, RNA Sciences
Adam PavlicekBioinformatics Consultant
Joseph E. PaynePresident & CEO, Director of the Board
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics Ltd. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Carlos Perez-GarciaSenior Scientist, Translational Biology
Natalie PrigozhinaAssociate Director, Drug Discovery
Kumar RajappanPrincipal Scientist, Chemistry
Scott RobertsSenior Manager, CMC
Marciano SabladScientist II, Translational Biology
Neda SafarzadehDirector, Investor Relations/Public Relations/Marketing
Hazel SantosAccounts Payable Specialist
Andrew SassineDirector of the Board
Andrew Sassine served on the Board of Directors of ICAD Inc. for two years. Mr. Sassine also serves on the board of directors of Nasdaq listed Gemphire Therapeutics, Inc.(GEMP), an early-stage cardiovascular drug company formed by a licensing agreement with Pfizer Inc. He also is Chairman of the Board of privately held ComHear Inc., a digital audio software and device company. Mr. Sassine previously served on the board of Acorn Energy, Inc, CNS Response, Inc. and FluoroPharma Medical, Inc., (FMPI). Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2004 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech between 2009 and 2014. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.
Kiyoshi TachikawaSenior Research Fellow, Frontier Science
Steve TanisChemistry Consultant
Wendy TaylorDirector, Project Management
Ramon Diaz TrellesScientist II, Frontier Science
Tran TrinhResearch Associate I, RNA Process Development
Jerel VegaSenior Research Associate, Formulation Development
Carina WimerResearch Associate II, Drug Discovery
Lishuang (Lily) XuResearch Associate II, Drug Discovery
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.
News & Events
July 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
June 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
May 31, 2018
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO